Vancomycin-Resistant Enterococci Outside the Health-Care Setting: Prevalence, Sources, and Public Health Implications

Emerging Infectious Diseases

Volumn 3, Issue 3, 1997, Pages 311-317

  McDonald, L Clifford ^a   Kuehnert, Matthew J ^a   Tenover, Fred C ^a   Jarvis, William R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AVOPARCIN; GLYCOPEPTIDE; VANCOMYCIN;

ANIMAL; ANIMAL FOOD; ANIMAL HUSBANDRY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CROSS INFECTION; DISEASE CARRIER; DRUG EFFECT; ENTEROCOCCUS; EUROPE; FOOD CONTROL; HUMAN; MICROBIOLOGY; PUBLIC HEALTH; REVIEW; UNITED STATES;

ANIMAL FEED; ANIMAL HUSBANDRY; ANIMALS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DISEASE RESERVOIRS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; EUROPE; FOOD MICROBIOLOGY; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PUBLIC HEALTH; UNITED STATES; VANCOMYCIN;

EID: 0031178966     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0303.970307     Document Type: Article

References (52)

1. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
2. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
3. Shay DK, Maloney SA, Monteclavo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
4. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible Enterococcus faecium. Clin Infect Dis 1996;22:663-70.
5. Handwerger S, Raucher B, Altarac D, Monka J, Marchione S, Singh KV, et al. Nosocomial outbreak due to E. faecium highly resisitant to vancomycin, penicillin, and gentamicin. Clin Inf Dis 1993;16:750-5.
6. Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, et al. Outbreak of vancomycin, ampicillin and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994;38:1363-7.
7. Edmond MB, Ober JF, Weinbaum JL, Pfaller MA, Hwang T, Sanford MD, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Inf Dis 1995;20:1126-33.
8. Chow JW, Kuritza A, Shlaes DM, Green M, Sahm DF, Zervos MJ. Clonal spread of vancomycin-resistant Enterococcus faecium between patients in three hospitals in two states. 1993;31:1609-11.
9. Sader HS, Pfaller MA, Tenover FC, Hollis RJ, Jones RN. Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers. J Clin Microbiol 1994;32:2840-2.
10. Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9.
11. Jordens JZ, Bates J, Griffiths DT. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1994;34:515-28.
12. Donnelly JP, Voss A, Witte W, Murray B. Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? [letter]. Antimicrob Chemother 1996;37:389-90.
13. Gordts B, Claeys K, Jannes H, Van Landuyt HW. Are vancomycin resistant enterococci (VRE) normal inhabitants of the GI tract of hospitalized patients? [abstract]. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando. Washington (DC): American Society for Microbiology; 1994. p. 145.
14. Endtz HA, Belkum N, Braak, N, Duin J, Kluijtmans J, Koeleman J, et al. Prevalence of vancomycin-resistant enterococci in hospital and community based patients in the Netherlands [abstract]. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington (DC): American Society for Microbiology; 1996. p. 37.
15. Bogaard A, London N, Driessen C, Stobberingh E. Prevalence of resistant fecal bacteria in turkeys, turkey farmers and turkey slaughterers [abstract]. In: Pro-gram and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington (DC): American Society for Microbiology; 1996. p. 86.
16. Bates J, Jordens JZ, Selkon JB. Evidence for an animal origin of vancomycin-resistant enterococci [letter]. Lancet 1993;342:490-1.
17. Klare I, Heier H, Claus H, Witte, W. Environmental strains of Enterococcus faecium with inducible high-level resistance to glycopeptides. FEMS Microbiol Lett 1993;106:23-30.
18. Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococci infection in man. J Antimicrob Chemother 1994;34:507-16.
19. Klare I, Heier H, Claus H, Witte W. VanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett 1995;125:165-72.
20. Aarestrup FM. Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Microb Drug Resist 1995;1:255-7.
21. Aarestrup FM, Ahrens P, Madsen M, Pallesen LV, Poulsen RL, Westh H. Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin. Antimicrob Agents Chemother 1996;40:1938-40.
22. Kruse H, Rorvik LM. The use of avoparcin as a growth promoter and the occurrence of vancomycin resistant Enterococcus spp. in poultry production [abstract]. In: Program and Abstracts of the 96th General Meeting of the American Society for Microbiology, New Orleans. Washington (DC): American Society for Microbiology; 1996. p. 36.
23. Klare I, Heier H, Claus H, Böhme G, Marin S, Seitmann G, et al. Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community. Microb Drug Resist 1995;1:265-73.
24. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993;175:117-27.
25. Handwerger S, Skoble J. Identification of a chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1995;39:2446-53.
26. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE, et al. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996;40:2605-9.
27. Bais RK, Freundlich LF, Currie BP. Outpatient prevalence of vancomycin-resistant enterococcal (VRE) enteric colonization in the catchment area of a hospital hyperendemic for VRE [abstract]. Infect Control Hosp Epidemiol 1996;17:20.
28. Landman D, Quale JM, Oydna E, Willey B, Ditore V, Zaman M, et al. Comparison of five selective media for identifying fecal carriage of vancomycin-resistant enterococci. J Clin Microbiol 1996;34:751-2.
29. Mato R, Delencastre H, Roberts RB, Tomasz A. Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York city hospital. Microb Drug Resist 1996;2:309-17.
30. Boyle JF, Soumakis SA, Rendo A, Herrington JA, Gianarkis DG, Thurberg BE, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993;31:1280-5.
31. Bontin, M, Slaughter S, Hayden M, Nathan C, Van Voorhis J, Rice T, et al. Patients' endogenous flora as a source of "nosocomial" vancomycin-resistant enterococci (VRE) [abstract]. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington (DC): American Society for Microbiology; 1996. p. 219.
32. Coque TM, Arduino RC, Murray BE. High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci. Clin Infect Dis 1995;20:1048-51.
33. Thal LA, Welton LA, Perri MB, Donabedian S, McMahon J, Chow JW, et al. Antimicrobial resistance in enterococci isolated from turkeys fed virginamycin [abstract]. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington (DC): American Society for Microbiology; 1996. p. 55.
34. Thai LA, Chow JW, Mahayni R, Bonilla H, Perri MB, Donabedian SA, et al. Characterization of antimicrobial resistance in enterococci of animal origin. Antimicrob Agents Chemother 1995;39:2112.
35. Harrison TS, Qaiyumi S, Morris JG, Bonilla H, Perri MB, Donabedian SA, et al. Incidence of multiply resistant enterococci in poultry [abstract]. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington (DC): American Society for Microbiology; 1995. p. 271.
36. Dunne WM, Dunne BS, Smith D. Watch out where the huskies go. American Society for Microbiology News 1996;62:283.
37. Van Belkum A, van den Braak N, Thomassen R, Verbrugh H, Endtz H. Vancomycin-resistant entero-cocci in cats and dogs [letter]. Lancet 1996;348:1038-1039.
38. Devriese LA, Ieven M, Goossens H, Vandamme P, Pot B, Hommez J, et al. Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob Agents Chemother 1996;40:2285-87.
39. Shekar R, Chico G, Bass SN, Strozewski K, Biddle J. Household transmission of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995;21:1511-2.
40. Howarth F, Poulter D. Vancomycin resistance: time to ban avoparcin? [letter]. Lancet 1996;347:1047.
41. Commission directive 97/6/EC of 30, January 1997 amending council directive 70/524/EEC concerning additives in feeding stuffs. Official Journal of the European Communities 1997;35:11-13.
42. Food and Drug Administration. Guilty verdict in veal feed case. Center for Veterinary Medicine [online] 1996; [cited 1996 Aug 29] [1 screen]. Available from: URL: http://www.cvm.fda.gov/fda/infores/updates/ vitek.html
43. Hayes PW, RH Gustaeson, FK Lotgering, et al. Reply to: Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? [letter] J Antimicrob Chemother 1996;37:390-2.
44. Mudd A. Vancomycin resistance and avoparcin [letter]. Lancet 1996;347:1312.
45. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA 1993;269:598-602.
46. Swartz MN. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci USA 1994;91:2420-7.
47. Whitman MS, Pitsakis PG, DeJesus E, Osborne AJ, Levison ME, Johnson CC. Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model. Antimicrob Agents Chemother 1996;40:1526-30.
48. Suppola JP, Volin L, Valtonen W, Vaara M. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996;23:694-7.
49. Van der Auwera P, Pensart N, Korten V, Murray BE, Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996;173:1129-36.
50. Panagea S, Chadwick PR. Heat tolerance of vancomycin resistant Enterococcus faecium. J Clin Pathol 1996;49:687-9.
51. Food and Drug Administration. Extralabel animal drug use; fluroquinolones and glycopeptides; notice of order of prohibition. Federal Register 1997;62:2744-7.
52. Centers for Disease Control and Prevention. Hospital Infection Control Practices Advisory Committee's recommendations for preventing the spread of vancomycin resistance. MMWR Morb Mortal Wkly Rep 1995;44:1-13.